Table 2
Univariate Cox-regression analysis for predicting OS and RFS in 246 HCC patients with PVTT with and without PA-TACE
| Factors | OS | RFS | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| Univariate analysis | ||||||
| Age (mean (SD),Years) | 1.000 | 0.99-1.02 | 0.584 | 0.990 | 0.98-1 | 0.096 |
| Sex (Male/Female) | 1.370 | 0.83-2.25 | 0.214 | 1.270 | 0.79-2.03 | 0.327 |
| Tumor Rupture (Yes/No) | 1.220 | 0.57-2.61 | 0.600 | 1.320 | 0.65-2.67 | 0.448 |
| Child-pugh (A/B) | 0.800 | 0.54-1.18 | 0.254 | 0.520 | 0.35-0.76 | 0.001 |
| HBsAg (Positive/Negative) | 0.950 | 0.6-1.49 | 0.826 | 1.360 | 0.88-2.12 | 0.167 |
| HBV-DNA (≥2000 /<2000 IU/mL) | 1.220 | 0.93-1.61 | 0.154 | 1.210 | 0.93-1.58 | 0.158 |
| Antiviral therapy (Yes/No) | 0.640 | 0.36-1.14 | 0.131 | 0.860 | 0.52-1.43 | 0.566 |
| AFP (>400/ ≤400 ng/ml) | 1.360 | 1.01-1.84 | 0.043 | 1.340 | 1.01-1.79 | 0.044 |
| Tbi (mean, μmol/L) | 1.000 | 1-1.01 | 0.069 | 1.000 | 1-1.01 | 0.272 |
| PALB (mean, g/L) | 1.000 | 1-1.00 | 0.634 | 1.000 | 1-1.00 | 0.211 |
| Alb (mean, g/L) | 1.000 | 0.96-1.04 | 0.926 | 0.970 | 0.93-1 | 0.068 |
| PLT (≥100/<100×109) | 1.100 | 0.73-1.68 | 0.649 | 1.320 | 0.89-1.97 | 0.168 |
| INR (mean) | 3.040 | 0.49-18.83 | 0.231 | 3.140 | 0.51-19.35 | 0.217 |
| Transfusion (Yes/No) | 1.410 | 1.07-1.87 | 0.016 | 1.270 | 0.97-1.68 | 0.088 |
| Type of resection (anatomical/nonanatomical) | 0.590 | 0.43-0.8 | 0.001 | 0.870 | 0.65-1.16 | 0.328 |
| Hilar clamping time (mean, minutes) | 0.990 | 0.98-1 | 0.076 | 1.000 | 0.99-1.02 | 0.557 |
| Tumor size, ≤5 cm | 1.00 (Reference) | 1.00 (Reference) | ||||
| 5 cm-10 cm | 1.550 | 1.01-2.37 | 0.044 | 1.360 | 0.93-1.99 | 0.111 |
| >5 cm | 2.290 | 1.49-3.51 | <0.001 | 1.760 | 1.19-2.61 | 0.004 |
| Tumor Number (>1/1) | 1.110 | 0.83-1.47 | 0.495 | 1.330 | 1.01-1.75 | 0.042 |
| Cirrhosis (Yes/No) | 1.090 | 0.82-1.44 | 0.567 | 1.110 | 0.85-1.46 | 0.449 |
| Tumor capsule, Complete | 1.00 (Reference) | 1.00 (Reference) | ||||
| Incomplete | 0.840 | 0.63-1.11 | 0.223 | 0.670 | 0.5-0.88 | 0.004 |
| Absent | 1.330 | 0.72-2.49 | 0.364 | 0.930 | 0.51-1.7 | 0.081 |
| Satellite lesions (Yes/No) | 1.340 | 0.9-1.98 | 0.148 | 1.360 | 0.93-1.99 | 0.113 |
| MVI (Yes/No) | 1.810 | 1.15-2.85 | 0.011 | 1.940 | 1.24-3.03 | 0.004 |
| Edmondson-Steiner grade (III-IV/II) | 1.150 | 0.77-1.71 | 0.501 | 2.080 | 1.38-3.14 | <0.001 |
| postHBsAg (Positive/Negative) | 0.950 | 0.6-1.49 | 0.826 | 1.360 | 0.88-2.12 | 0.167 |
| postHBV-DNA(≥2000 /<2000 IU/mL) | 1.200 | 0.91-1.58 | 0.207 | 1.410 | 1.08-1.84 | 0.012 |
| postAFP (>400/≤400 ng/ml) | 1.720 | 1.3-2.27 | <0.001 | 1.540 | 1.17-2.02 | 0.002 |
| postTbi (mean, μmol/L) | 1.020 | 1.01-1.02 | <0.001 | 1.000 | 1-1.01 | 0.243 |
| postAlb (mean, g/L) | 1.000 | 1-1.01 | 0.114 | 1.000 | 1-1.00 | 0.718 |
| postPLT (≥100/<100×109) | 0.950 | 0.65-1.39 | 0.796 | 1.280 | 0.89-1.83 | 0.179 |
| postINR (mean) | 3.330 | 0.9-12.31 | 0.071 | 1.260 | 0.36-4.39 | 0.717 |
| postAntiviral therapy (Yes/No) | 0.330 | 0.19-0.58 | <0.001 | 0.890 | 0.58-1.38 | 0.609 |
| PA-TACE (No/Yes) | 2.240 | 1.67-3.02 | <0.001 | 3.960 | 2.94-5.32 | <0.001 |
Bold values indicate statistical significance (P < 0.05). OS, overall survival; RFS, recurrence-free survival. HCC, hepatocellular carcinoma; PVTT, Portal Vein Tumor Thrombus; AFP, α-fetoprotein; Tbi, total bilirubin; PALB, prealbumin; Alb, albumin; PLT, blood platelet; INR, international normalized ratio; MVI, microvascular invasion.